| Next 10 |
Ad
BAYRY News and Press Bayer AG ADR
home / stock / bayry / bayry news
News | Bayer AG ADR (OTCMKTS:BAYRY)
-
2024-10-09 12:22:20 ET More on Bayer Bayer: Speculative Value Beyond Litigation Pressures Bayer: Risks Remain While Business Is Stabilizing Bayer: Why I'm Careful, But Rate It Buy Read the full article on Seeking Alpha For further details see: Bay...
-
2024-10-04 14:02:06 ET More on pharma, biotech companies Pfizer: Patent Fears Priced In Lock In A Phenomenal Yield With Pfizer Pfizer: Growth From Oncology Franchise; Initiate With 'Buy' Bristol-Myers wins FDA nod for Opdivo lung cancer indica...
-
2024-09-24 09:03:50 ET More on Amgen, Regeneron, etc. Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript) Amgen Inc. (AMGN) Wells Fargo 2024 Healthcare Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanle...
-
2024-09-21 16:00:07 ET Novartis: Another Beat, Another Raise Why Novartis Deserves Your Attention After Q2 2024 Results Novartis AG (NVS) Q2 2024 Earnings Call Transcript Novartis Kisqali gains early breast cancer indication J&J leads H1 healthcare de...
-
2024-09-19 16:27:32 ET Summary Organon announced the acquisition of ROIV's Dermavant for $1.2 billion to enhance its dermatology portfolio. The deal includes ROIV's VTAMA cream, which is FDA-approved for plaque psoriasis and under review for atopic dermatitis. This deal also poten...
-
2024-09-16 15:40:04 ET More on AstraZeneca AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data AstraZeneca PLC (AZN) Q2 2024 Earnings Call Transcript AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings Astra...
-
2024-09-10 06:59:50 ET More on Bayer, Bayer AG, etc. Bayer: Speculative Value Beyond Litigation Pressures Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript Immunovant st...
-
2024-09-07 01:13:50 ET Summary Bayer's Q2 2024 results were mixed, with strong Pharmaceuticals performance offsetting challenges in Crop Science and stable Consumer Health results. The reaffirmation of full-year guidance and a significant legal win in the "Schaffner vs. Monsanto" ...
-
2024-09-05 13:16:14 ET More on Perspective Therapeutics The Prognosis For Perspective Therapeutics BofA starts Perspective at buy, cites use of radioactive Lead-212 Seeking Alpha’s Quant Rating on Perspective Therapeutics Historical earnings data for P...
-
2024-09-05 13:16:14 ET More on Perspective Therapeutics The Prognosis For Perspective Therapeutics BofA starts Perspective at buy, cites use of radioactive Lead-212 Seeking Alpha’s Quant Rating on Perspective Therapeutics Historical earnings data for P...
Stock Information
Get BAYRY Alerts
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
Ad
-
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
-
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
Important Investor News Alert (OTC: AABB)
-
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - October 9, 2024) - Investorideas.com , a global investor news source covering mining and metals stocks releases a snapshot looking at recent news and updates with gold stocks featuring Asia Broadband Inc. (OTC: AABB), a resource ...